Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm wondering if this is a good idea to buy @ 4.40 or 4.30 and put a stop loss @ 4 or 3.90
What do you think?
I'm going to put an order to buy @ $3 ....
Do you think the market value will drop by the end og the month if the X millions warrants are converted?
Sold all my position.
Now, I just want this stock to crash
But I don't think it will happen.
Maybe tomorrow it will touch $6 or $6.5
Reason of the rally, I think:
http://www.businessweek.com/news/2013-09-10/uralkali-sees-support-for-potash-price-above-300-on-asia-demand
Maybe he is going to buy Prospect Global.
Sold yesterday 1500 @ $4
Sold today 1000 @ 5.30
remain: 1064.
I think I will keep them.
If it goes up, good, if it goes back to $3, I will buy again.
Let's see
Or put an order to sell @$6, and they play with another stock.
Who was the guy that sold his position @$2.00 something? LOL
Do you think this rally could be the same as the one we had in june?
and then the big dive?
On a position of 3050 units, I have sold 1500 @ 4.00 (could sold them @ 4.5, but thought too much).
Now, if it drops to 3 or below, I will buy again, if it continues to 6 or 7$, I will have my 2050 units available.
I think that's not bad.
Almost the equivalent of 35 millions shares traded today.
Again, one week ago we were like with an average of 300'00?!
ppfff
What is your flat point?
My flat point is $6.20...........
Let's see If I will see this level again one day
yeah I know, I was kidding.
I always look on google finance. Yahoo is never accurate.
ok, but who uses yahoo??!!
When I think yahoo, I see Altavista.
What is the total shares now? 2.3M, is this correct?
When you think about the volumes we had previously, now more than 500k per day is just amazing.
something is happening here, but don't know what.
hope it will not be like 3 months ago where we went from 0.12 to 0.30 and then the big dive.
$2.88 not that bad. If we do +30% everyday, that's fine..
back on track£?
apparently, in the after maker we are now @ 2.57 (google finance) Let's se tomorrow....
-30% after the reverse split. What a joke.
I would like to see the face of the guys who invested 5M @ 0.12 (if I remember well) with some warrants. 0.12... and now it's like we are @ 0.045...
Actual volume of 161'000 is like 8'000'000 before the RS.
not that bad.
We will reach $2 by the end of the week.
And then 1$ in one or two weeks.
Then it will go under 1$, and the company is going to receive a warning saying that the stock is under 1$ for more than X days... then reverse split, etc.
pppffff
I Think you are right. But as I have some $$$ invested, I will not believe you
I think nobody can say where this stock is going.
Can go to $1 in 2 weeks, or stay between 2.5 and 3.5 for months or do a big jump.
But my little finger tells me that he thinks this stock has more chances to go to 1$ than 9$
The reverse split has now been done.
Let's see what is gong to happen next day -weeks.
We are now at 3.06, it will go down, then they will increase the shares, the price will fall, we will reach 0.07 again and then reverse split again, till they start the extraction of the potash.
I will put a stop loss. Have to see at what level. Maybe 2 or 2.5
Ladies & Gentlemen, start your engines... .-)
Dear all,
Today seems that the volume is increasing...
I have a big holding on ILNS and I think something is going to come in the near future.
Monday, December 27, 2010 9:35 AM
Share Price of Intellect Neurosciences, Inc. (ILNS.OB) Up on Alzheimer’s Drug News
By QualityStocks
Intellect Neurosciences, Inc., a biotechnology company with several drugs in various stages of development, released more data today regarding it lead Alzheimer’s candidate, OX1 (Oxigon™), which has recently completed a Phase 1b clinical trial. After releasing data in late October showing that the drug was well tolerated and safe at all dosing levels, the Company announced that it has received a pharmacokinetic profile report from a fourteen-day safety trial.
OX1 is a unique molecule that is being proven effective at promoting clearance of soluble beta amyloid and also blocks neurotoxicity that is created by free radicals. This neurotoxicity damages synaptic function in the brain which results in irreversible changes in the nerve cells.
The study, sponsored by Intellect and conducted by Kendle through the Kendle Clinical Pharmacology Unit in Utrecht, The Netherlands, was a double-blind, randomized, placebo-controlled, multiple escalating doses between three groups of twelve healthy, elderly volunteers over 60 years in age. The patients in the dosing group consisted of eight subjects which were given doses of 200, 400 or 800 mgs of OX1 at six hour intervals.
The new pharmacokinetic data indicates that the drug is rapidly absorbed and distributed in the body after oral administration. Moreover, the terminal elimination half-life increased from approximately 6-8 hours on the first day of the trial to 8-9 hours on the fourteenth day. This new data suggests that the drug could be administered less frequently than realized from the Phase I trials. In planning for the Phase II clinical trials, this data will now be factored as the Company plans to demonstrate the effects of OX1 in Alzheimer’s patients on a relevant biomarker in the cerebrospinal fluid.
Additional good news accompanied this pharmacokinetic data as well today as Intellect announced that they have been informed that the National Institute of Aging, a part of the National Institute of Health, will support the toxicology studies for OX1, which are slated to begin in the first part of 2011. This is part of a federal initiative to work at many levels and with many different companies and academics in a quest to find a therapy for Alzheimer’s disease. The National Institute of Aging has already worked with Intellect by giving support in the key safety and toxicology studies for OX1.
Due to the urgency to find a treatment for Alzheimer’s, Intellect is moving itself into a solid position within the industry and has become a subject of interest of larger biotechnology companies. According to Dr. Daniel Chain, Chairman and Chief Executive Officer of Intellect, “We have received interest from several large pharmaceutical companies regarding OX1 and anticipate partnering this drug in the future. We look forward to moving forward with our clinical and regulatory development plan that includes the filing of an Investigational New Drug application (IND) with the FDA to support initiation of Phase 2 trials. Typically, licenses and or collaborations with large pharmaceutical companies yield substantial revenues from license fees, development milestone payments and royalties from sales.”
More information on Intellect Neurosciences, Inc. and its pipeline of compounds can be found on the Company’s website at www.intellectns.com.
Hi everybody!
I just jumped in!
Bought some stocks @ 0.0025
investments it's an individual "activity".
There is no socialism, sorry.
$27'000 invested.
From a no big to be at flat, I prefer be at flat and have my cash.
Hi all.
Bought 136M shares more than one month ago @0.0002, and was a little bit scared with the no bid.
Just sold almost all my holding at flat.
Will invest my money on another stock..
good luck to all.
please explain...
@Luca
You know, I've alreay bought some shares in the past. I've written how many shares I had, and some of the masters of this forum told me that was a "bad" thing to say here, how many shares we are holding.
I've made good profits on last jump in august.
So, let's see the next one...
just bought some shares...
Hi everybody...
what a joke..or is he really so ambicious? lol
Mr. Lovatt discussed Cloud Centric Systems goal of meeting the OTC Market requirements to qualify for its OTCQX market tier. The Company will work to maintain its Current Information Status on Pink Sheets and will eventually file a 15C -211 through a broker/dealer in the near future. Mr. Lovatt stated, "The OTCQX is for growth companies like Cloud Centric Systems that desire future listing on the NASDQ or NYSE."
""old" news
I'm quite optimistic. if I'm right, I remember that google has bought a company that offer also this kind of "cloud" technology...
Sep 13 2010
Cloud Centric Systems, Inc. VizualMobile Secures Int’l Pre-Launch Interest
Cloud Centric Systems, Inc. VizualMobile Secures Int’l Pre-Launch Interest
CLDR tech firm receives distribution requests from channel partners in EurAsia
LONDON--(09/13/10) - Cloud Centric Systems, Inc. (Pinksheets:CLDR) announces today that its newly acquired tech firm, VizualMobile is nearing the completion of a key Phase of development on its premier product platform which will allow firms to manage mobile phone accounts of employees, regardless of their platform/carrier. “The platform, which include seamless accessibility for Google’s Android, Apple’s Iphone (IOS) and RIM Blackberry platforms, has provided some interesting challenges, which our development team is meeting with confident capability, all under budget and on time,” states Cloud Centric Systems CEO, David Lovatt.
He continues, “The market has an ever-increasing demand for a product like ours. Progress with both product development and feedback from strategic partners reinforces that the timing for Cloud Centric’s acquisition of VizualMobile is very much conducive to industry trends, but more specifically, to CLDRs strategic development phase and overall company growth and expansion,” adds Lovatt.
A recent wireless industry report comments on the future of managed mobile security systems:
As the smartphone market continues to expand, companies want to support each type of device rather than define a single device as a corporate standard. Furthermore, the ultimate ability today to support multiple mobile devices such as Android, BlackBerry, the iPad, the iPhone and the Symbian OS has a broad appeal to companies of all sizes.
With MaaS (mobility as a service) being positioned as an alternative for companies that normally would have to build their own mobility security solutions, the market is ripe for wireless carriers, operators and system integrators to offer these new revenue-generating services.
MMSS (managed mobility security services) will help retain customers and gain new ones, create additional revenue streams and better leverage economies of scale to deliver services quickly to new customers.
Cloud Centric also confirms today that, as a result of discussions with channel partners worldwide, the VizualMobile platform development and its applications have garnered “tremendous interest from some of the more technologically advanced countries in the world,” states Lovatt, “primarily in Europe and Asia, including Singapore as well as enormous response from China. We expect to have Letters of Intent and/or solidified Distribution Agreements during Q3/Q4 that cover most of our Key Territories.”
.About Cloud Centric Systems: Cloud Centric Systems specializes in cloud based technologies that use the Internet to deliver business critical applications via a global network of partners. Cloud Centric Systems plans to grow via strategic acquisition over the coming 12 months as well as strong sales through its subsidiaries.
For more information, please visit www.cloudcentricsystems.com
Safe Harbor Statement:
The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company's control.
Release drafted by NMR, LLC
CLDR contact:
Investor Relations
1 (347) 404 5346